Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in 2009 have been widely adopted as end points in a number of recent clinical trials. However, evidence exists that they do not predict response or provide clinically relevant measures of benefit for the patients. This article presents revised recommendations for assessing response in ET and PV provided by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment. New definitions of complete and partial remission incorporate clinical, hematological, and histological response assessments that include a standardized symptom assessment form and consider absence of disease progression and vascular events. We anticipate that these criteria will be adopted widely to facilitate the development of new and more effective therapies for ET and PV.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674675 | PMC |
| http://dx.doi.org/10.1182/blood-2013-01-478891 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disconnection between sugars reduction and calorie reduction in baked goods and breakfast cereals with sugars-related nutrient content claims in the Canadian marketplace.
Front Nutr
February 2025
Faculty of Land and Food Systems, University of British Columbia, Vancouver, BC, Canada.
Introduction: Nutrition claims aim to highlight key attributes in foods and assist consumers to make informed dietary choices. Consumers generally perceive products with claims related to lower sugars content as being healthier. Food manufacturers also use these claims to highlight reformulation action in response to consumer demands and government policies.
View Article and Find Full Text PDFA formal statechart model of immediate neonatal adaptation guidelines.
Heliyon
February 2025
Universidad Nacional de Colombia, Sede Bogotá, Facultad de Medicina, Departamento de Pediatría, Bogotá, Colombia.
Research highlights the importance of applying physiological criteria for optimal umbilical cord clamping, underlining its lasting advantages. In response, the Division of Pediatrics, Perinatology, and Neonatology at the National University of Colombia has pioneered the Immediate Neonatal Adaptation Guideline, focusing on Physiologically-based Cord Clamping. This study has two main objectives: The first is to represent the medical guideline through a statechart model to enhance clarity and detail.
View Article and Find Full Text PDFIntroduction: This study aims to assess the feasibility, acceptability, and validity of EQ-5D instrument administration methods and proxy selection for evaluating health-related quality of life (HRQoL) in dementia populations. EQ-5D is a widely used measure of HRQoL and is recommended by the National Institute for Health and Care Excellence for cost-effectiveness analyses of health interventions.
Methods: Individual-level data from three trials were analyzed separately to evaluate missing data rates, inter-rater agreement, responsiveness, and predictors of EQ-5D (EQ-5D-3L and EQ-5D-5L) dimensions and index values.
Rethinking Pediatric Sepsis and Septic Shock: Beyond International Consensus Criteria.
Pediatric Health Med Ther
March 2025
Department of Pediatrics, Faculty of Clinical Medicine and Dentistry, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda.
Purpose/objective: International pediatric sepsis consensus definitions play a critical role in evidence-based clinical practice, providing standardized tools for case identification. However, a common misconception is treating sepsis as a static diagnosis rather than recognizing it as a dynamic and evolving process. It is essential to integrate consensus criteria into a broader, more flexible clinical approach rather than applying them rigidly.
View Article and Find Full Text PDFOncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series.
J Cachexia Sarcopenia Muscle
April 2025
Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Background: In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!